Developer docs
API playgroundTry for free, no card

Search company profiles

Emery Pharma

Full company profile

uuid000bfff

Namestring
Emery Pharma
Legal namestring
Emery Pharma
Websiteurl
emerypharma.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Emery Pharma is a Contract Research Organization (CRO) founded in 2011 and headquartered in Alameda, California, delivering customized analytical, bioanalytical, microbiological, and consulting services to pharmaceutical and biotechnology companies across the drug development lifecycle. The company operates a single-site laboratory at 1000 Atlantic Ave Suite #110, staffed by a small team of PhD-level scientists and analytical chemists, and maintains the regulatory credential stack required for regulated pharmaceutical work — FDA registration, DEA licensing for controlled substances, GLP and cGMP certification, and ISO/IEC 17025 compliance for extractables and leachables studies.

The laboratory's technical platform is anchored in mass spectrometry and chromatography: High Resolution Orbitrap and triple-quadrupole LC-MS/MS systems, 400 MHz NMR, UPLC with CAD/DAD/RI detectors, GC-MS/FID, and the Meso Scale Discovery electrochemiluminescence immunoassay platform, complemented by an extensive bacterial strain collection including ESKAPE pathogens and multidrug-resistant clinical isolates. Service lines span analytical method development and validation (ICH Q2(R2), USP <1224>), impurity analysis and profiling (nitrosamines, benzene, elemental impurities under ICH Q3D), pharmaceutical stability testing, extractables and leachables, biologics characterization (peptide mapping, intact mass, PTM, HCP, DAR for ADCs, biosimilar comparability), bioanalytical and DMPK/DDI services, formulation development, metabolomics, botanical drug development, and cell and microbiology services.

Emery Pharma generates revenue through project-based contracts with enterprise pharmaceutical and biotechnology clients, with pricing tailored to scope, complexity, and regulatory tier (GLP/cGMP vs. R&D) and billed under multi-year contract cadences. Go-to-market is sales-led via direct enterprise engagement and a "Request a Proposal" funnel, supported by content marketing through a scientific blog and resources library. The company also offers consulting and litigation support for patent, product liability, and regulatory matters. Customer segments are primarily traditional pharma and biotech, with a secondary segment of virtual biotechs and program teams lacking internal analytical infrastructure.

Short descriptiontext

Emery Pharma is a private, FDA-registered and GLP/cGMP-certified Contract Research Organization in Alameda, California, providing analytical, bioanalytical, biologics characterization, microbiology, and impurity testing services to pharmaceutical and biotechnology clients across drug development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, analytical laboratory testing, bioanalytical services, biologics characterization, impurity analysis profiling
Industry4 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Medicinal Chemicals & Botanical Products2833
Product category
Contract Research Organization (Pharmaceutical Analytical & Bioanalytical Laboratory Services)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Emery Pharma generates revenue through providing customized contract research laboratory services to pharmaceutical and biotechnology clients. Services include analytical method development, bioanalytical services, stability testing, impurity analysis, biologics characterization, and cell/microbiology services. The revenue model is project-based with quotes tailored to client outsourcing needs.

emerypharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

CRO services are quoted on a project-by-project basis depending on service type, complexity, turnaround time requirements, and regulatory compliance level (GLP/cGMP vs R&D).

emerypharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Emery Pharma is a Contract Research Organization (CRO) providing GLP/cGMP-compliant laboratory services to pharmaceutical and biotechnology companies. Its core offerings include analytical chemistry and method development/validation, bioanalytical testing for PK/PD and DMPK, biologics characterization (including ADCs and biosimilars), impurity analysis (nitrosamines, benzene, elemental impurities), extractables and leachables studies, formulation development, stability testing, cell and microbiology services, botanical drug development, and consulting/expert-witness support. All engagements are project-based and customized to client outsourcing needs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Projects delivered on time
+2 more records
Product overview1 text field

Emery Pharma is a Contract Research Organization (CRO) delivering a comprehensive portfolio of laboratory services for pharmaceutical and biotechnology drug development. The company operates as a GLP/cGMP-compliant laboratory providing analytical services (including method development, validation, LC-MS, NMR, HPLC, GC-MS, high-resolution mass spectrometry, proteomics, and metabolomics), bioanalytical services (including DMPK, DDI bioanalysis, ELISA, MSD immunoassays, and qualitative bioanalysis), cell and microbiology services (including antibiotic resistance testing and antimicrobial synergy studies), impurity analysis and profiling services (including nitrosamine and benzene testing), extractables and leachables studies, formulation development, pharmaceutical stability testing, biologics characterization services, botanical drug development support, and consulting and litigation support. The company maintains state-of-the-art instrumentation including Orbitrap mass spectrometers, triple quad LC-MS/MS systems, HPLC/UPLC platforms, GC-MS, and NMR spectroscopy. These services support preclinical and clinical drug development from early-stage research through regulatory submissions.

Product and service19 records
1Analytical Services
CategoryAnalytical Chemistry Laboratory Services
Description

Full-service analytical chemistry laboratory supporting preclinical drug development including method development and validation, LC-MS services, NMR services, HPLC/UPLC, GC-MS, high-resolution mass spectrometry, proteomics, metabolomics, and reference standard synthesis for pharmaceutical and biotechnology sponsors.

2Biologics Characterization Services
CategoryBiologics Analytical Services
Description

Comprehensive analytical support for proteins, antibodies, and complex biologics including peptide mapping, intact mass analysis, post-translational modification analysis, host-cell protein analysis, comparability studies, and drug-antibody ratio analysis for ADC characterization for biopharmaceutical sponsors.

3Extractables and Leachables (E&L) Studies
CategoryExtractables and Leachables Testing
Description

Controlled extraction studies and leachables stability testing for pharmaceutical and medical device products following ISO/IEC 17025 guidelines, including Soxhlet, reflux, and sonication extraction techniques and analytical techniques such as LC-MS, GC-MS, ICP-MS, and NMR.

4Pharmaceutical Release Testing Services
CategoryRelease and Compendial Testing
Description

cGMP-compliant release testing and compendial assay services including compendial methods testing (USP/NF, EP/JP) and custom validated release assay development for APIs, biologics, peptides, and oligonucleotides per ICH Q2(R2) guidelines.

5Impurity Analysis and Profiling Services
CategoryImpurity Analysis and Profiling
Description

Detection, quantitation, and characterization of organic and inorganic impurities including degradation products, residual solvents, process-related impurities, and elemental contaminants following ICH Q3, ICH M7, ICH Q3D, and USP <232>/<233> guidelines for pharmaceutical and biotechnology sponsors.

6Pharmaceutical Stability Testing Services
CategoryPharmaceutical Stability Testing
Description

Comprehensive stability testing services under ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C guidelines including custom R&D stability studies and ICH-compliant long-term, intermediate, and accelerated studies across all climate zones for pharmaceutical and biotechnology sponsors.

7Analytical Method Development, Transfer & Validation Services
CategoryAnalytical Method Development and Validation
Description

GLP/GMP-compliant method development, validation, and transfer services for small molecules, biologics, oligonucleotides, and peptides using LC-MS/MS, UPLC, NMR, HRMS, GC-MS, and LBA platforms following ICH Q2(R2) and USP <1224> guidelines for pharmaceutical and biotechnology sponsors.

8Benzene Impurity Analysis
CategorySpecialty Impurity Testing
Description

Specialized analytical testing for detection and quantitation of benzene impurities in drug substances and products using Headspace Gas Chromatography with Mass Spectrometry (HS-GC/MS) supporting compound-specific risk assessment and regulatory compliance for pharmaceutical clients.

9Formulation Development Services
CategoryFormulation Development
Description

Drug formulation development services including pre-formulation studies, formulation trials, functional assays (dissolution testing, IVRT/IVPT), stability assessments, and scalability support from prototype through commercial batches for pharmaceutical sponsors.

10Metabolomics Services
CategoryMetabolomics and Mass Spectrometry Services
Description

Comprehensive metabolomics analysis including targeted metabolomics, untargeted metabolomics, lipidomics, and metabolomic flux analysis using UPLC-HRMS, UPLC-QqQ-MS/MS, GC-MS, and NMR platforms for pharmaceutical and biotechnology clients.

11Bioanalytical Services
CategoryBioanalytical Services
Description

Mass spectrometry-based bioanalysis supporting pharmacokinetics, pharmacodynamics, and drug metabolism studies with LC-MS/MS, HRMS, and GC-MS platforms following ICH M10 guidelines for GLP and non-GLP sample analysis for pharmaceutical and biotechnology sponsors.

12DMPK and Drug-Drug Interaction Bioanalytical Services
CategoryDMPK and DDI Bioanalysis
Description

DMPK and DDI bioanalytical services including PK bioanalysis, immunogenicity and anti-drug antibody testing, CYP enzyme induction/inhibition studies, metabolite analysis, and in vitro ADME assays (Caco-2, PAMPA, hepatocyte stability, microsomal stability) for pharmaceutical and biotechnology sponsors.

13ELISA and MSD Immunoassays
CategoryImmunoassay Services
Description

Immunoassay services for large molecule quantitation including custom ELISA development and validation, MSD (Meso Scale Discovery) multiplex assay development, pharmacokinetics and pharmacodynamics biomarker analysis, and immunogenicity testing (ADA, nAb) for biopharmaceutical sponsors.

14Ligand Binding Assays
CategoryLigand Binding Assay Services
Description

Ligand binding assay services including ELISA development, binding kinetics analysis, and regulatory-compliant assay validation for drug development and clinical diagnostics applications for pharmaceutical and biotechnology sponsors.

15Qualitative Bioanalysis Services
CategoryQualitative Bioanalysis / MetID
Description

Metabolite identification and characterization (MetID) and untargeted metabolomics analysis using NMR, LC-HRMS, GC-MS, and LC-MS/MS platforms for drug metabolism studies and biomarker discovery for pharmaceutical and biotechnology sponsors.

16Botanical Drug Development Services
CategoryBotanical Drug Development
Description

Specialized services for botanical drug discovery and development including analytical chemistry, biochemistry, formulation science, natural products characterization, and regulatory submissions support from IND through clinical trials for botanical and natural product pharmaceutical sponsors.

17Cell & Microbiology Services
CategoryCell and Microbiology Services
Description

Microbiological characterization services including antibiotic resistance testing with multidrug-resistant clinical isolates and ESKAPE pathogens, antimicrobial synergy studies, biofilm eradication testing, cytotoxicity testing, MIC determination, and time-kill kinetics assays for pharmaceutical and biotechnology clients.

18Nitrosamine Testing Services
CategorySpecialty Impurity Testing (Nitrosamines)
Description

Specialized nitrosamine impurity analysis services for pharmaceutical products including method development and validation under cGMP conditions for detection and quantitation of N-nitrosamine compounds for pharmaceutical clients responding to regulatory nitrosamine concerns.

19Consulting & Litigation Support Services
CategoryScientific Consulting and Litigation Support
Description

Expert analytical analysis and litigation support services provided by leading scientists in drug development for pharmaceutical legal disputes including patent litigation, product liability cases, and regulatory investigations for legal teams, sponsors, and regulatory bodies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Emery Pharma and Rayner announced a successful publication validating a bioanalytical method for quantifying ketorolac in human vitreous and aqueous humor using a surrogate matrix of human plasma, in accordance with ICH M10 guidelines. This collaboration demonstrates joint scientific expertise in ophthalmic bioanalysis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global testing giant with extensive pharmaceutical services including bioanalytical, stability, impurity analysis, E&L and GMP release testing — broad incumbent that competes with Emery Pharma across nearly every service line at larger scale.

TypeBroad incumbent
Description

Integrated CRO offering bioanalytical, CMC, biologics and impurity testing services — overlapping with Emery Pharma in regulated small-molecule and biologics analytical testing.

TypeDirect peer
Description

Specialty CRO providing bioanalytical, DMPK, and drug metabolism services including in vitro ADME and LC-MS/MS quantification — overlapping with Emery Pharma's DMPK/DDI and bioanalytical services.

TypeDirect peer
Description

Specialty bioanalytical CRO focused on LC-MS/MS PK, immunogenicity and biomarker assays — closest mid-sized U.S. peer to Emery Pharma's bioanalytical services.

TypeDirect peer
Description

Specialty bioanalytical CRO focused on LC-MS/MS, immunogenicity (ADA/nAb), biomarker and PK analysis — closely comparable to Emery Pharma's bioanalytical, ELISA/MSD and DMPK offerings.

TypeDirect peer
Description

U.S.-headquartered bioanalytical and CMC CRO offering LC-MS/MS, HRMS, biologics characterization and method development — directly overlapping Emery Pharma's bioanalytical and analytical service portfolio for small molecules and biologics.

TypeBroad incumbent
Description

Large preclinical and bioanalytical CRO offering regulated bioanalysis, biologics characterization, microbiology and GMP testing services — competes for the same enterprise client programs from a much broader portfolio.

TypeBroad incumbent
Description

Global CRO/CDMO providing bioanalytical, CMC, biologics characterization and impurity testing — overlapping with Emery Pharma's analytical and bioanalytical work, though at much larger scale.

TypeBroad incumbent
Description

Global CRO offering bioanalytical, biomarker, central lab and GMP-compliant testing services — broad incumbent competing for the same regulated assay work.

TypeBroad incumbent
Description

Global CRO with extensive bioanalytical, GMP lab and biologics characterization services — competes with Emery Pharma for enterprise biopharma analytical and bioanalytical work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance13 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emery Pharma

Contract Research Organization (Pharmaceutical Analytical & Bioanalytical Laboratory Services)emerypharma.com

Emery Pharma is a private, FDA-registered and GLP/cGMP-certified Contract Research Organization in Alameda, California, providing analytical, bioanalytical, biologics characterization, microbiology, and impurity testing services to pharmaceutical and biotechnology clients across drug development.

What Emery Pharma does

Emery Pharma is a Contract Research Organization (CRO) founded in 2011 and headquartered in Alameda, California, delivering customized analytical, bioanalytical, microbiological, and consulting services to pharmaceutical and biotechnology companies across the drug development lifecycle. The company operates a single-site laboratory at 1000 Atlantic Ave Suite #110, staffed by a small team of PhD-level scientists and analytical chemists, and maintains the regulatory credential stack required for regulated pharmaceutical work — FDA registration, DEA licensing for controlled substances, GLP and cGMP certification, and ISO/IEC 17025 compliance for extractables and leachables studies.

The laboratory's technical platform is anchored in mass spectrometry and chromatography: High Resolution Orbitrap and triple-quadrupole LC-MS/MS systems, 400 MHz NMR, UPLC with CAD/DAD/RI detectors, GC-MS/FID, and the Meso Scale Discovery electrochemiluminescence immunoassay platform, complemented by an extensive bacterial strain collection including ESKAPE pathogens and multidrug-resistant clinical isolates. Service lines span analytical method development and validation (ICH Q2(R2), USP <1224>), impurity analysis and profiling (nitrosamines, benzene, elemental impurities under ICH Q3D), pharmaceutical stability testing, extractables and leachables, biologics characterization (peptide mapping, intact mass, PTM, HCP, DAR for ADCs, biosimilar comparability), bioanalytical and DMPK/DDI services, formulation development, metabolomics, botanical drug development, and cell and microbiology services.

Emery Pharma generates revenue through project-based contracts with enterprise pharmaceutical and biotechnology clients, with pricing tailored to scope, complexity, and regulatory tier (GLP/cGMP vs. R&D) and billed under multi-year contract cadences. Go-to-market is sales-led via direct enterprise engagement and a "Request a Proposal" funnel, supported by content marketing through a scientific blog and resources library. The company also offers consulting and litigation support for patent, product liability, and regulatory matters. Customer segments are primarily traditional pharma and biotech, with a secondary segment of virtual biotechs and program teams lacking internal analytical infrastructure.

Emery Pharma firmographics

Firmographics
Name
Emery Pharma
Legal name
Emery Pharma
Website
https://emerypharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Emery Pharma is a private, FDA-registered and GLP/cGMP-certified Contract Research Organization in Alameda, California, providing analytical, bioanalytical, biologics characterization, microbiology, and impurity testing services to pharmaceutical and biotechnology clients across drug development.
Ownership category
akta.pro rank

Emery Pharma industry classification

Industry
Product category
Contract Research Organization (Pharmaceutical Analytical & Bioanalytical Laboratory Services)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Contract research services
  • Analytical laboratory testing
  • Bioanalytical services
  • Biologics characterization
  • Impurity analysis profiling

Where Emery Pharma is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Emery Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services: Emery Pharma generates revenue through providing customized contract research laboratory services to pharmaceutical and biotechnology clients. Services include analytical method development, bioanalytical services, stability testing, impurity analysis, biologics characterization, and cell/microbiology services. The revenue model is project-based with quotes tailored to client outsourcing needs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Emery Pharma product offering

Product offering

Core offering

Emery Pharma is a Contract Research Organization (CRO) providing GLP/cGMP-compliant laboratory services to pharmaceutical and biotechnology companies. Its core offerings include analytical chemistry and method development/validation, bioanalytical testing for PK/PD and DMPK, biologics characterization (including ADCs and biosimilars), impurity analysis (nitrosamines, benzene, elemental impurities), extractables and leachables studies, formulation development, stability testing, cell and microbiology services, botanical drug development, and consulting/expert-witness support. All engagements are project-based and customized to client outsourcing needs.

Product overview

Emery Pharma is a Contract Research Organization (CRO) delivering a comprehensive portfolio of laboratory services for pharmaceutical and biotechnology drug development. The company operates as a GLP/cGMP-compliant laboratory providing analytical services (including method development, validation, LC-MS, NMR, HPLC, GC-MS, high-resolution mass spectrometry, proteomics, and metabolomics), bioanalytical services (including DMPK, DDI bioanalysis, ELISA, MSD immunoassays, and qualitative bioanalysis), cell and microbiology services (including antibiotic resistance testing and antimicrobial synergy studies), impurity analysis and profiling services (including nitrosamine and benzene testing), extractables and leachables studies, formulation development, pharmaceutical stability testing, biologics characterization services, botanical drug development support, and consulting and litigation support. The company maintains state-of-the-art instrumentation including Orbitrap mass spectrometers, triple quad LC-MS/MS systems, HPLC/UPLC platforms, GC-MS, and NMR spectroscopy. These services support preclinical and clinical drug development from early-stage research through regulatory submissions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Analytical Services Full-service analytical chemistry laboratory supporting preclinical drug development including method development and validation, LC-MS services, NMR services, HPLC/UPLC, GC-MS, high-resolution mass spectrometry, proteomics, metabolomics, and reference standard synthesis for pharmaceutical and biotechnology sponsors.
  • Biologics Characterization Services Comprehensive analytical support for proteins, antibodies, and complex biologics including peptide mapping, intact mass analysis, post-translational modification analysis, host-cell protein analysis, comparability studies, and drug-antibody ratio analysis for ADC characterization for biopharmaceutical sponsors.
  • Extractables and Leachables (E&L) Studies Controlled extraction studies and leachables stability testing for pharmaceutical and medical device products following ISO/IEC 17025 guidelines, including Soxhlet, reflux, and sonication extraction techniques and analytical techniques such as LC-MS, GC-MS, ICP-MS, and NMR.
  • Pharmaceutical Release Testing Services cGMP-compliant release testing and compendial assay services including compendial methods testing (USP/NF, EP/JP) and custom validated release assay development for APIs, biologics, peptides, and oligonucleotides per ICH Q2(R2) guidelines.
  • Impurity Analysis and Profiling Services Detection, quantitation, and characterization of organic and inorganic impurities including degradation products, residual solvents, process-related impurities, and elemental contaminants following ICH Q3, ICH M7, ICH Q3D, and USP <232>/<233> guidelines for pharmaceutical and biotechnology sponsors.
  • Pharmaceutical Stability Testing Services Comprehensive stability testing services under ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C guidelines including custom R&D stability studies and ICH-compliant long-term, intermediate, and accelerated studies across all climate zones for pharmaceutical and biotechnology sponsors.
  • Analytical Method Development, Transfer & Validation Services GLP/GMP-compliant method development, validation, and transfer services for small molecules, biologics, oligonucleotides, and peptides using LC-MS/MS, UPLC, NMR, HRMS, GC-MS, and LBA platforms following ICH Q2(R2) and USP <1224> guidelines for pharmaceutical and biotechnology sponsors.
  • Benzene Impurity Analysis Specialized analytical testing for detection and quantitation of benzene impurities in drug substances and products using Headspace Gas Chromatography with Mass Spectrometry (HS-GC/MS) supporting compound-specific risk assessment and regulatory compliance for pharmaceutical clients.
  • Formulation Development Services Drug formulation development services including pre-formulation studies, formulation trials, functional assays (dissolution testing, IVRT/IVPT), stability assessments, and scalability support from prototype through commercial batches for pharmaceutical sponsors.
  • Metabolomics Services Comprehensive metabolomics analysis including targeted metabolomics, untargeted metabolomics, lipidomics, and metabolomic flux analysis using UPLC-HRMS, UPLC-QqQ-MS/MS, GC-MS, and NMR platforms for pharmaceutical and biotechnology clients.
  • Bioanalytical Services Mass spectrometry-based bioanalysis supporting pharmacokinetics, pharmacodynamics, and drug metabolism studies with LC-MS/MS, HRMS, and GC-MS platforms following ICH M10 guidelines for GLP and non-GLP sample analysis for pharmaceutical and biotechnology sponsors.
  • DMPK and Drug-Drug Interaction Bioanalytical Services DMPK and DDI bioanalytical services including PK bioanalysis, immunogenicity and anti-drug antibody testing, CYP enzyme induction/inhibition studies, metabolite analysis, and in vitro ADME assays (Caco-2, PAMPA, hepatocyte stability, microsomal stability) for pharmaceutical and biotechnology sponsors.
  • ELISA and MSD Immunoassays Immunoassay services for large molecule quantitation including custom ELISA development and validation, MSD (Meso Scale Discovery) multiplex assay development, pharmacokinetics and pharmacodynamics biomarker analysis, and immunogenicity testing (ADA, nAb) for biopharmaceutical sponsors.
  • Ligand Binding Assays Ligand binding assay services including ELISA development, binding kinetics analysis, and regulatory-compliant assay validation for drug development and clinical diagnostics applications for pharmaceutical and biotechnology sponsors.
  • Qualitative Bioanalysis Services Metabolite identification and characterization (MetID) and untargeted metabolomics analysis using NMR, LC-HRMS, GC-MS, and LC-MS/MS platforms for drug metabolism studies and biomarker discovery for pharmaceutical and biotechnology sponsors.
  • Botanical Drug Development Services Specialized services for botanical drug discovery and development including analytical chemistry, biochemistry, formulation science, natural products characterization, and regulatory submissions support from IND through clinical trials for botanical and natural product pharmaceutical sponsors.
  • Cell & Microbiology Services Microbiological characterization services including antibiotic resistance testing with multidrug-resistant clinical isolates and ESKAPE pathogens, antimicrobial synergy studies, biofilm eradication testing, cytotoxicity testing, MIC determination, and time-kill kinetics assays for pharmaceutical and biotechnology clients.
  • Nitrosamine Testing Services Specialized nitrosamine impurity analysis services for pharmaceutical products including method development and validation under cGMP conditions for detection and quantitation of N-nitrosamine compounds for pharmaceutical clients responding to regulatory nitrosamine concerns.
  • Consulting & Litigation Support Services Expert analytical analysis and litigation support services provided by leading scientists in drug development for pharmaceutical legal disputes including patent litigation, product liability cases, and regulatory investigations for legal teams, sponsors, and regulatory bodies.

Quantifiable outcome

  • Projects delivered on time
  • +2 more outcomes

Companies that use Emery Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Emery Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

Emery Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RaynerminorStrategic or Co-development PartnerEmery Pharma and Rayner announced a successful publication validating a bioanalytical method for quantifying ketorolac in human vitreous and aqueous humor using a surrogate matrix of human plasma, in accordance with ICH M10 guidelines. This collaboration demonstrates joint scientific expertise in ophthalmic bioanalysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emery Pharma competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Global testing giant with extensive pharmaceutical services including bioanalytical, stability, impurity analysis, E&L and GMP release testing — broad incumbent that competes with Emery Pharma across nearly every service line at larger scale.
  • Pharmaron: Integrated CRO offering bioanalytical, CMC, biologics and impurity testing services — overlapping with Emery Pharma in regulated small-molecule and biologics analytical testing.
  • Charles River Laboratories: Large preclinical and bioanalytical CRO offering regulated bioanalysis, biologics characterization, microbiology and GMP testing services — competes for the same enterprise client programs from a much broader portfolio.
  • WuXi AppTec / WuXi STA: Global CRO/CDMO providing bioanalytical, CMC, biologics characterization and impurity testing — overlapping with Emery Pharma's analytical and bioanalytical work, though at much larger scale.
  • IQVIA Laboratories: Global CRO offering bioanalytical, biomarker, central lab and GMP-compliant testing services — broad incumbent competing for the same regulated assay work.
  • PPD (Thermo Fisher Scientific): Global CRO with extensive bioanalytical, GMP lab and biologics characterization services — competes with Emery Pharma for enterprise biopharma analytical and bioanalytical work.

Direct peers

  • Bioanalytical Systems (BASi): Specialty CRO providing bioanalytical, DMPK, and drug metabolism services including in vitro ADME and LC-MS/MS quantification — overlapping with Emery Pharma's DMPK/DDI and bioanalytical services.
  • MicroConstants: Specialty bioanalytical CRO focused on LC-MS/MS PK, immunogenicity and biomarker assays — closest mid-sized U.S. peer to Emery Pharma's bioanalytical services.
  • KCAS Bioanalytical & Biomarker Services: Specialty bioanalytical CRO focused on LC-MS/MS, immunogenicity (ADA/nAb), biomarker and PK analysis — closely comparable to Emery Pharma's bioanalytical, ELISA/MSD and DMPK offerings.
  • Frontage Laboratories: U.S.-headquartered bioanalytical and CMC CRO offering LC-MS/MS, HRMS, biologics characterization and method development — directly overlapping Emery Pharma's bioanalytical and analytical service portfolio for small molecules and biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Emery Pharma compliance and trust

Trust signal

Compliance13 records

Emery Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emery Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Emery Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emery Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emery Pharma

What does Emery Pharma do?

Emery Pharma is a Contract Research Organization (CRO) providing GLP/cGMP-compliant laboratory services to pharmaceutical and biotechnology companies. Its core offerings include analytical chemistry and method development/validation, bioanalytical testing for PK/PD and DMPK, biologics characterization (including ADCs and biosimilars), impurity analysis (nitrosamines, benzene, elemental impurities), extractables and leachables studies, formulation development, stability testing, cell and microbiology services, botanical drug development, and consulting/expert-witness support. All engagements are project-based and customized to client outsourcing needs.

Is Emery Pharma a public or private company?

Emery Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Emery Pharma founded?

Emery Pharma was founded in 2011. It employs 11 to 50 people.

Where is Emery Pharma based?

Emery Pharma is headquartered in Alameda, United States, in the North America region.

How does Emery Pharma make money?

One revenue line is on record: contract Research Services.

Who are Emery Pharma's main competitors?

Broad incumbents on record are Eurofins Scientific, Pharmaron, Charles River Laboratories, WuXi AppTec / WuXi STA, IQVIA Laboratories and PPD (Thermo Fisher Scientific). Direct peers are Bioanalytical Systems (BASi), MicroConstants, KCAS Bioanalytical & Biomarker Services and Frontage Laboratories.

Does Emery Pharma have an API?

No public API is recorded for Emery Pharma.

What industry is Emery Pharma in?

Emery Pharma's product category is Contract Research Organization (Pharmaceutical Analytical & Bioanalytical Laboratory Services). Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireFortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using RifampinFortrea and Emery Pharma announced a collaboration to provide FDA-compliant rifampin impurity testing for drug-drug interaction studies. The partnership enables sponsors to use rifampin, which has faced scrutiny over nitrosamine impurities, with updated FDA guidance raising acceptable limits. The collaboration aims to de-risk early-phase trials and accelerate timelines.Stock TitanFortrea Partners With Emery Pharma for FDA-Compliant Drug Interaction TestingFortrea and Emery Pharma announced a collaboration to provide FDA-compliant testing of rifampin's nitrosamine impurity MNP for drug-drug interaction studies. The partnership enables sponsors to use rifampin, which the FDA raised its acceptable MNP limit for in 2023. The service is now available to Fortrea customers conducting clinical pharmacology trials.GlobeNewswireFortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using RifampinFortrea and Emery Pharma announced a collaboration to provide FDA-compliant rifampin impurity testing for drug-drug interaction studies. The partnership enables sponsors to use rifampin, which has faced scrutiny over nitrosamine impurities, with updated FDA guidance raising acceptable limits. The collaboration aims to de-risk early-phase trials and accelerate timelines.PR NewswireCentivax and Emery Pharma Partner to Accelerate Universal Vaccine Clinical ReadinessCentivax and Emery Pharma announced a partnership to develop an IND-enabling GLP-compliant potency release assay for Centi-Flu, a pan-influenza universal vaccine. The assay will validate manufactured vaccine doses for clinical and post-approval use. The collaboration aims to accelerate vaccine development and support follow-on universal vaccines.GlobeNewswireEmery Pharma Announces New Biologics Analytical DivisionEmery Pharma expanded its laboratories with a High-Resolution Orbitrap Mass Spectrometer and new instruments for UPLC, GC-MS, and HPLC. The company appointed Dr. Rodney Bannwart to lead its new Large Molecule Analytical Division, supporting R&D for biologics and antibody-drug conjugates.NewswireEmery Pharma Announces New Biologics Analytical DivisionEmery Pharma expanded its laboratories with a High-resolution Orbitrap Mass Spectrometer and new instruments to support biologics and antibody-drug conjugate R&D. Dr. Rodney Bannwart was appointed to lead the new Large Molecule Analytical Division, bringing experience from Pfizer, Abbott, Novartis, and Alcon.PR NewswireEmery Pharma Files an FDA Citizen Petition on Vitamin B6 Toxicity and Urges Warning LabelEmery Pharma filed a Citizen Petition with the FDA on September 20, 2021, requesting the recall of all over-the-counter mega-dose Vitamin B6 products and the addition of warning labels due to the risk of severe and potentially irreversible neurotoxicity. The petition highlights that 28-36% of the US population uses supplements containing Vitamin B6, while mega-doses of 50-500 mg per day remain widely available OTC despite other regulatory bodies in the UK, EU, and Australia setting upper limits between 10-50 mg daily. The company previously filed a successful citizen petition regarding NDMA in Ranitidine (Zantac), which led to that product's recall from the US market.BevNET.comVertosa Announces U.S. Patent: Engages Emery Pharma For Research That Applies Their Pharmaceutical Development Expertise to Cannabis-Infused ProductsVertosa announced a U.S. patent for its core emulsion formula, used since 2019 with brands like Vita Coco EU and WUNDER. The company partnered with Emery Pharma to conduct pharmacokinetic studies on emulsified CBD and THC, with results expected this summer. The studies aim to compare product formats and support industry growth.PR NewswireHalodine Engages Emery Pharma for Next Generation Development of Oral and Nasal Antiseptics Active Against SARS-CoV-2 (COVID-19)Halodine LLC announced a collaboration with Emery Pharma to advance the development of Halodine's proprietary antiseptic platform for potential COVID-19 interventions. The partnership will evaluate Halodine's products against drug-resistant ESKAPE pathogens, biofilm-forming agents, and oral pathogens, as well as test efficacy against beta-coronavirus (OC-43) as a surrogate for SARS-CoV-2. Emery Pharma will leverage its microbiology, virology, and bioanalytical capabilities, including its proprietary betacoronavirus assay, to support the development of Halodine's antiseptic products for use in sinus disease, hospital-associated infections, and oral decontamination.PR NewswireCP Lab Safety and Emery Pharma Launch Onsite COVID-19 Screening and Testing Service for Businesses NationwideCP Lab Safety and Emery Pharma have launched REVEAL, an onsite COVID-19 screening service for businesses in partnership with DiaCarta, offering both RT-PCR and antibody tests. The program initially targets the San Francisco Bay Area with plans to expand nationwide using trained medical professionals to administer tests that return results within 48 hours. This initiative aims to help employers safely reopen workplaces by detecting infections and identifying asymptomatic carriers.